PRECISION BIOSCIENCES Business Summary

Precision BioSciences (DTIL) is an advanced gene editing company utilizing its proprietary ARCUS platform, a synthetic genome editing engine derived from naturally occurring homing endonucleases, to develop in vivo genetic medicines. The company generates revenue primarily through high-value strategic collaborations and licensing agreements with global pharmaceutical leaders, including Eli Lilly, Novartis, and TG Therapeutics, which provide upfront payments, R&D funding, and milestone-based incentives. Its business segments are concentrated on its in vivo pipeline, specifically targeting infectious diseases like Chronic Hepatitis B (PBGENE-HBV) and genetic disorders such as Primary Mitochondrial Myopathy (PBGENE-PMM). Within the competitive landscape, DTIL competes directly with CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics. Unlike these competitors who largely utilize CRISPR/Cas9 or base editing, Precision differentiates itself through the ARCUS platform’s smaller size and high specificity, positioning it as a specialized player in complex gene insertions and mitochondrial DNA editing. The leadership team is anchored by Chief Executive Officer Michael Amoroso, who brings extensive commercial and operational experience from his previous roles at Abeona Therapeutics and Celgene. The company’s scientific foundation rests on its co-founders, including Chief Scientific Officer Derek Jantz, PhD, a pioneer in protein engineering who co-invented the ARCUS technology. Supporting the financial and strategic trajectory is Chief Financial Officer John Alexander Kelly, who previously held senior leadership positions at Novartis and Bausch Health. The Board of Directors features industry veterans such as Chairman Kevin Murphy, providing deep expertise in biopharmaceutical scaling and capital markets. Precision has historically attracted backing from institutional investors like FMR LLC and Arrowmark Partners, reinforcing its position as a technically distinct contender in the genomic medicine sector.